A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
Sponsor: |
Aveo Pharmaceuticals |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ6970 |
U.S. Govt. ID: |
NCT02627963 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug sorafenib which works in a similar way to tivozanib. Tivozanib and sorafenib are both called study medication. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer. This study will look at the effects of tivozanib on subjects with refractory advanced renal cell cancer.
This study is closed
Investigator
Emerson Lim, MD
Have you been diagnosed with renal cell cancer? |
Yes |
No |